Lineage Cell Therapeutics Inc. — Director's Dealing 2012

Apr 27, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2012-04-24

Reporting Person: WEST MICHAEL D (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-04-24	Common Shares, no par value	M	20000	$0.74	Acquired	99600	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-04-24	Option to Purchase Common Shares	$0.74	M	20000	Disposed	2012-04-30	Common Shares (20000)	Direct

Footnotes

F1: Does not include shares that may be acquired upon the exercise of certain stock options.

F2: 5,000 options became exercisable on May 1, 2007 and the remaining 15,000 became exercisable in 3 equal quarterly installments based upon continued service on the board of directors.